Ongoing trials put focus back on fatty liver disease

By EASL December 12,2017

With the ongoing success in the efforts to cure patients with hepatitis C, this year's Liver Meeting saw a shift in focus to new science in fatty liver disease, including important clinical drug trials. One area of interest came from investigators lamenting the lack of a reliable, accurate, noninvasive method to diagnose and stage the degree of liver injury in patients with NASH. Allen and colleagues[1] examined the role of a multiparametric magnetic resonance elastography (MRE) protocol for the detection of NASH before the onset of fibrosis in obese subjects. Multifrequency three-dimensional (3D) MRE (at 30, 40, and 60 Hz) was used to determine which viscoelastic imaging parameters correlated with early histologic changes in patients with NASH scheduled to undergo bariatric surgery.

To read the full article, visit: Medscape